Médecine nucléaire, Institut Curie, Hôpital Paris, 26 rue d'Ulm, 75005, Paris, France.
Médecine nucléaire, Hôpital Tenon, Assistance Publique-Hôpitaux de Paris, 4 rue de la Chine, 75020, Paris, France.
BMC Cancer. 2018 Apr 13;18(1):417. doi: 10.1186/s12885-018-4335-4.
We aimed to assess the prognostic value of CYFRA 21-1 in a series of patients with anal canal squamous cell carcinoma treated by radiation-based therapy.
All patients with anal cancer referred between September 2005 and July 2013 were considered. Patients with diagnosis of anal squamous cell carcinoma and in whom pre- and post-treatment serum CYFRA 21-1 levels were available were included. Serum CYFRA 21-1 levels at initial workup and after therapy were collected. Survival rates were estimated using the Kaplan-Meier method. Cox regression analysis was used to evaluate prognostic variables for prediction of outcomes.
Eighty-two patients were included. Median follow-up was 60 months (range: 8-128). Pre-treatment serum CYFRA 21-1 levels were significantly correlated with tumour stage (p < 0.001). Normal post-treatment serum CYFRA 21-1 level was significantly correlated with tumour complete response (p = 0.004). Elevated post-treatment serum CYFRA 21-1 level was significantly associated with poorer progression-free survival (p = 0.02) and overall survival (p = 0.003). T stage and post-treatment serum CYFRA 21-1 were independent prognostic factors for overall survival (p = 0.04 and 0.03, respectively).
Serum CYFRA 21-1 appears to be a useful marker for the monitoring of anal squamous cell carcinoma patients. Elevated post-treatment value appears to be correlated with treatment failure.
我们旨在评估 CYFRA 21-1 在一系列接受基于放射治疗的肛门管鳞癌患者中的预后价值。
考虑了 2005 年 9 月至 2013 年 7 月间转诊的所有肛门癌患者。纳入了诊断为肛门鳞癌且有治疗前后血清 CYFRA 21-1 水平的患者。收集了初始检查和治疗后血清 CYFRA 21-1 水平。使用 Kaplan-Meier 方法估计生存率。使用 Cox 回归分析评估预测结果的预后变量。
共纳入 82 例患者。中位随访时间为 60 个月（范围：8-128）。治疗前血清 CYFRA 21-1 水平与肿瘤分期显著相关（p<0.001）。正常治疗后血清 CYFRA 21-1 水平与肿瘤完全缓解显著相关（p=0.004）。治疗后血清 CYFRA 21-1 水平升高与无进展生存期（p=0.02）和总生存期（p=0.003）较差显著相关。T 分期和治疗后血清 CYFRA 21-1 是总生存期的独立预后因素（p=0.04 和 0.03）。
血清 CYFRA 21-1 似乎是监测肛门鳞癌患者的有用标志物。治疗后升高的值似乎与治疗失败有关。
